Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) generates a steady flow of news as a commercial-stage biopharmaceutical company focused on vaccines for infectious diseases. News coverage commonly highlights developments related to its adult hepatitis B vaccine HEPLISAV-B®, its CpG 1018® adjuvant platform, and a growing pipeline of adjuvanted vaccine candidates.
Investors and observers following DVAX news will see regular updates on financial results, including quarterly earnings releases filed via Form 8-K, where Dynavax reports HEPLISAV-B net product revenue, total revenues, and adjusted EBITDA, along with commentary on market share trends in the U.S. adult hepatitis B vaccine market. These releases often include forward-looking guidance and discussion of capital allocation decisions such as share repurchase authorizations.
Another major category of Dynavax news involves clinical and pipeline milestones. The company issues press releases on topline data from its Phase 1/2 shingles vaccine trial for Z-1018, describing immunogenicity, tolerability and head-to-head comparisons with Shingrix®. Additional updates cover progress in its plague vaccine program funded by the U.S. Department of Defense, its pandemic influenza adjuvant program using CpG 1018 with H5N1 influenza vaccine, and its investigational Lyme disease vaccine candidate.
Corporate and strategic news items include participation in healthcare investor conferences, announcements of conference calls and webcasts, and collaboration agreements. Notably, Dynavax and Vaxart announced an exclusive license and collaboration for an investigational oral COVID-19 vaccine candidate, and Sanofi has announced an agreement to acquire Dynavax through a cash tender offer and subsequent merger, subject to customary conditions.
By tracking the DVAX news feed, readers can monitor how Dynavax’s commercial performance, clinical data, collaborations and corporate transactions evolve over time. This page aggregates company press releases and related disclosures so that users can review financial updates, pipeline progress and strategic announcements in one place.
Dynavax Technologies (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on vaccine development, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Interested parties can access the webcast through the company's investor relations website, with a replay available for 30 days. Participants are advised to register and connect 10 minutes before the call.
Dynavax Technologies (Nasdaq: DVAX) reported strong Q2 2024 financial results, highlighting record HEPLISAV-B net product revenue of $70.2 million, a 24% year-over-year increase. The company reaffirmed its full-year 2024 HEPLISAV-B net product revenue guidance of $265 - $280 million. Dynavax's total estimated market share in the U.S. increased to approximately 42%, with significant growth in retail pharmacy and IDN segments.
The company initiated dosing in a Phase 1/2 trial for its novel shingles vaccine program, with clinical data expected in 2H 2025. Dynavax also provided updates on its Tdap and plague vaccine programs. Financially, the company reported total revenues of $73.8 million, a 22% year-over-year increase, and net income of $11.4 million or $0.09 per share basic. Cash and marketable securities stood at $735.6 million as of June 30, 2024.
Dynavax Technologies (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on innovative vaccines, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024, after U.S. financial markets close. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET/1:30 p.m. PT.
Investors can access the live audio webcast through the 'Events & Presentations' page on the company's website. A replay will be available for 30 days following the event. To participate in the call, attendees must register using the provided caller registration link. It is recommended that participants join the conference call or webcast approximately 10 minutes before the scheduled start time.
Dynavax Technologies (Nasdaq: DVAX) has initiated a Phase 1/2 clinical trial of its investigational shingles vaccine, Z-1018. The study will assess the vaccine’s safety, tolerability, and immunogenicity in approximately 440 healthy adults aged 50-69 years in Australia. Z-1018, which uses the CpG 1018 adjuvant, aims to provide improved tolerability and strong CD4+ T-cell responses compared to the market-leading Shingrix® vaccine. The trial will determine the optimal dose and schedule for future studies and validate a Patient Reported Outcome measurement tool for differentiating Z-1018 on tolerability. Top-line results are expected in the second half of 2025.
Dynavax Technologies (Nasdaq: DVAX), a biopharmaceutical company focused on innovative vaccines, will present at two investor conferences in June 2024. The company will participate in the William Blair 44th Annual Growth Stock Conference on June 4 at 1:20 PM CT and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10 at 4:00 PM ET. Webcasts of these presentations will be accessible on the company's website.
Dynavax Technologies (Nasdaq: DVAX) announced that the U.S. FDA has issued a Complete Response Letter (CRL) regarding its supplemental Biologics License Application (sBLA) for a four-dose HEPLISAV-B vaccine regimen for adults on hemodialysis. The CRL cited insufficient data to fully evaluate the effectiveness and safety of the regimen, due to the destruction of data source documents and an inadequate sample size in the HBV-24 study. This decision does not impact the current approved indications for HEPLISAV-B in the U.S., EU, and Great Britain, nor the European Commission's approval of the four-dose regimen for hemodialysis patients. Dynavax plans to meet with the FDA to explore options for providing additional data.
Dynavax reported $48 million in HEPLISAV-B vaccine net product revenue, a 10% increase year-over-year in Q1 2024. The company reaffirmed its full-year revenue guidance and FDA clearance to initiate Phase 1/2 trial of Z-1018 shingles program. Dynavax continues to evaluate strategic growth opportunities while focusing on expanding its hepatitis B vaccine market share.
Summary not available.
Summary not available.
Summary not available.